Thyroid hormone (T 3 ) regulates proliferation and differentiation of cells, via its nuclear receptors (TRs
Introduction
Renal clear cell carcinoma (RCCC) constitutes~80% of all renal neoplasms and is the cause of death in 10 000 cases per year (1) . Most cases are sporadic and the molecular genetics underlying this disease are largely unknown. Only a few genes have been suggested to be involved in the carcinogenesis of RCCC. The best known is the von Hippel-Lindau tumor suppressor gene (VHL), which was found to be mutated in 57% of RCCC, and loss of heterozygosity (LOH) was observed in 98% of tumor samples (2) . Recent studies have shown that hypermethylation of the VHL promoter may contribute to its inactivation (3) . Other tumor suppressor genes involved in the pathogensis of RCCC are FHIT (4, 5) , NRC-1 (6) and unknown genes localized in the 3p21 region (7) (8) (9) .
Thyroid hormones regulate growth, development and differentiation. Their action is mediated by the thyroid hormone nuclear receptors (TRs), which are derived from two genes, TRα and TRβ, located on chromosomes 17 and 3, respectively (10) . Each gene gives rise to two receptor isoforms, α1, α2, β1 and β2, by alternative splicing of the primary transcripts. The gene regulating activity of TRs is mediated by binding to specific DNA sequences, known as thyroid hormone response elements (TREs), located on the promoter regions of thyroid hormone target genes. Recent studies have indicated that the gene regulatory functions of TR are modulated by formation of different heterodimers with other members of the receptor superfamily, notably the retinoic X receptors (RXRs) (10, 11) , by differential interaction with different types of TREs (10) and by interaction with various co-activators, co-repressors and other cellular proteins (10, 12) .
Increasing evidence has suggested that aberrant expression and/or mutations in TR genes could be associated with carcinogenesis. A reduction in the expression of mRNA for TRβ1 and TRβ2 was implicated in inappropriate expression of the glycoprotein hormone α-subunit gene in non-functioning tumors (NFTs) of the anterior pituitary and was proposed to contribute to uncontrolled tumor growth (13, 14) . Reduced expression of TRβ1 was also found in poorly differentiated fibroblast-like osteosarcoma (15) . However, in poorly differentiated hepatocarcinomas, overexpression of TRβ1 was correlated with enhanced thyroid hormone (T 3 )-induced proliferation (16, 17) . These results suggest that aberrant expression of TRs may be associated with different types of tumors and/or different states of differentiation. Furthermore, LOH of the chromosomal regions where TR genes are located (3p21-p25 for the TRβ gene and 17q21 for the TRα gene) was a frequent event in tumors (18) (19) (20) (21) . For example, LOH of the TRβ gene was observed in most of the small cell lung cancers examined (20, 22) , in 60% of posterior uveal melanomas (23) , 30% of breast (24) and 64% of non-familial renal cell carcinomas (25) . Consistent with these observations, microdeletion of both TRα alleles was found in 20% of gastrointestinal tumors (26) . LOH of the TRα gene was also observed in 79% of breast (27) and prostate cancers (28) . In addition to LOH in regions in which TRα and TRβ genes are located, high frequencies of mutant TRs (65% of TRα1 and 76% of TRβ1 in 17 tumors) with impaired function were identified in human hepatocellular carcinoma (17) . TRα1 mutants (13% of 23 tumors) were also found in NFTs of the anterior pituitary (14) .
We had previously found aberrant expression of TRα and TRβ mRNAs in RCCC (29) . Expression of both TRα1 and TRα2 mRNAs was reduced, while TRβ1 mRNA was overexpressed in 30% and significantly reduced in 70% of tumors examined. We hypothesized that these aberrant expression patterns may reflect mutations in TR genes leading to an alteration in expression. In the present study we have cloned TR cDNAs from tumors obtained from RCCC patients. We found multiple mutations in both the TRα and TRβ genes, resulting in impairment of T 3 and DNA binding and loss of transcriptional activity. The functional impairment in these mutants may contribute to the carcinogenesis of RCCC. 3 (2200 Ci/mmol) was obtained from DuPont-New England Nuclear (Boston, MA). pcDNA3.1, a eukaryotic expression vector, and Lipofectamine were purchased from Invitrogen (Carlsbad, CA) and Life Technologies (Grand Island, NY), respectively. The pGEM-T vector systems and TNT coupled reticulocyte system were obtained from Promega (Madison, WI). pBluescript KS(-) was obtained from Strategene (La Jolla, CA). The T7 expression plasmids for w-TRβ1 (pCJ3) and w-TRα1 (pCLC13) and the mammalian plasmids expressing TRβ1 (pCLC51) and w-TRα1 (pCLC61) were prepared as described (30) .
Materials and methods

Reagents
Tissues
Tissues were kindly provided by Dr A.Tanski of the Department of Urology, Vouvodoship Hospital (Ostroleka, Poland) with the permission of the Ethical Committee on Human Studies, Medical Center of Postgraduate Education, during unilateral nephrectomies following the diagnosis of kidney cancer. Fragments of the tumors, fragments of the opposite poles of the same kidney (not infiltrated with cancer) and fragments of the kidneys with no cancer were excised, immediately frozen on dry ice and stored at -75°C until needed. In total, 22 tumor tissues, 20 corresponding controls and seven non-cancerous kidney tissues were collected. Upon histological evaluation, the renal clear cell cancer diagnosis and tumor borders were established. Tumors were divided into the three groups depending on the grade of differentiation: G1, well differentiated (four tumors); G2, moderately differentiated (10 tumors); G3, undifferentiated cancers (eight tumors). Additionally, they were divided according to the TNM (tumor, nodules and metastases) classification of malignant tumors (31) .
RNA isolation
RNA was isolated according to Chomczynski (32) . Up to 100 mg deep frozen kidney tissue was manually homogenized in a glass-teflon homogenizer directly in 1 ml of TRI reagent (Molecular Research Center, Cincinnati, OH). Samples were incubated at room temperature for 5-10 min, supplemented with 0.2 ml of chloroform, mixed by shaking for 15 s, incubated at room temperature for 10 min and then centrifuged at 12 000 g for 15 min at 4°C. The upper, aqueous phase was transferred to another Eppendorf tube, mixed with 0.5 ml of isopropyl alcohol, incubated at room temperature for 15 min and then centrifuged at 12 000 g for 15 min at 4°C. The RNA pellet was washed with 75% ethanol, air dried and resuspended in 40-50 µl of DEPCtreated water. Purity of the RNA was evaluated by formaldehyde-agarose electrophoresis and the concentration determined by spectrophotometric measurements.
Cloning of TR cDNAs from kidney cancer tissues
To clone TRα1 and TRβ1 cDNAs in kidney cancer tissues as well as in normal tissues, RT-PCR was performed using a Superscript One-Step RT-PCR System (Life Technologies, Grand Island, NY) or Ready To Go RT-PCR beads (Amersham Pharmacia Biotech). Occasionally the reactions were supplemented with magnesium to a final concentration of up to 3 mM. To clone TR cDNAs, the following primers were used: for TRα1, forward primer 5Ј-GGATGGAATTGTGAATG-3Ј or 5Ј-ATGGAACAGAAGCCAAGCAA-3Ј and reverse primer 5Ј-GGCCGCCTGAGGCTTTA-3Ј; for TRβ1, forward primer 5Ј-GATCCAGAATGATTACTAACC-3Ј and reverse primer 5Ј-GGAA-TTATAGGAAGGAA TCC-3Ј and then internal primers, forward 5Ј-CTATAA-CCCCCAACAGTATG-3Ј or 5Ј-ATGACAGAAAATGGCCTTAC-3Ј and reverse, 5Ј-CTAATCCTCGAACACTTCCA-3Ј. Total RNA (0.5-1 µg) was used as a template in each RT-PCR reaction. Prior to each RT-PCR, RNA was denatured at 80°C for 5 min, cooled to room temperature and then supplemented with enzyme mix. Reverse transcription was performed at 48 or 42-43°C for 30 min. Reverse transcriptase was inactivated by incubation of the samples at 94°C for 2-3 min. cDNA amplification was performed using the following conditions: 40 cycles of 94°C for 40-50 s, 52°C for 1-1.5 min and 72°C for 2.5 min, followed by 10 min incubation at 72°C. In addition, since the amount of TRβ1 was very low after RT-PCR, a second PCR was performed with the above described internal primers. RT-PCR products were 26 electrophoresed on 1% agarose gels, then the gel fragment at the expected TRβ1 size was excised, dissolved in 100 µl of dH 2 O and 5 µl of this solution was used as template in a second PCR: 3 min at 94°C, 25 cycles of 94°C for 40-50 s and 52°C for 1 min, then 72°C for 2 min, followed by 10 min incubation at 72°C.
TRβ1 or TRα1 cDNAs derived from RT-PCR were electrophoresed on 1% agarose gels, excised and extracted from the gel with a QiaQuick Gel Extraction Kit (Qiagen, Valencia, CA), and then ligated into vector pGEM-T containing T overhangs (Promega, Madison, WI). JM 109 bacteria were transformed with the ligation mix and blue-white selection was performed. Mini-preps were carried out using the Wizard Plus SV Minipreps DNA Purification System (Promega, Madison, WI) or Plasmid Miniprep Plus kits (A&A Biotechnology, Gdansk, Poland). Restriction analyses were carried out to confirm the correct cloning (TRα1 with NcoI and TRβ1 with BstXI) in the pGEM-T vector. In the preliminary studies we have validated the above cloning procedure by isolating wild-type TRs from nomal kidneys and confirmed the sequences of wild-type TRs by sequencing.
Identification of mutation sites by sequencing of TRs isolated from kidney cancer tissues
To identify mutations in TRs isolated from tissues, the TR cDNAs cloned in the pGEM-T vector were sequenced by automatic sequencing using a BigDye Terminator Cycle Sequencing Kit (Perkin Elmer) using T7 and SP6 as primers. Mutation was confirmed by repeated sequencing of the same clone as well as other clones (up to four) originating from the same tumor. Sequence analysis was examined with Lasergene software (DNAstar, Madison, WI). As a control, wild-type TRβ1 was cloned from non-cancerous kidneys and sequenced to validate the cloning and to confirm the accuracy of sequencing reactions.
Cloning of TRβ1 and TRα1 mutants into pBluescript KS(-)
For efficient in vitro transcription/translation of mutant proteins, three TRα1 mutants (23TRα1, 2TRα1 and 6TRα1) and one TRβ1 mutant (18TRβ1) were recloned into the pBluscript KS(-) expression vector, which utilizes T7 as the promoter. The TR cDNAs were cut from the pGEM-T vector with the restriction enzymes SpeI and ApaI and cloned into the same sites in the pBluscript KS(-) expression vector, which was confirmed by restiction analyses using BstXI or NcoI for TRα1 and BstXI or PstI with SpeI for TRβ1.
Cloning of the TRβ1 and TRα1 mutants into a eukaryotic expression vector
The same TRα1 and TRβ1 mutants described above, positioned with their 5Ј-ends next to the SP6 promoter within the pGEM-T vector, were cut from this vector with NotI and ApaI and subcloned into vector pcDNA 3.1(ϩ) (Invitrogen, Carlsbad, CA), previously prepared with the same enzymes. To confirm correct cloning of the inserts, restriction analysis was performed with NcoI (TRα1 clones) or BstXI (TRβ1 clones). The remaining six mutated TRβ1 mutants, positioned with their 5Ј-ends next to the T7 promoter within the pGEM-T vector, were restricted with NcoI, treated with Klenow fragment (to blunt ends), phenol/chloroform and gel purified, then restricted with NotI and cloned into pcDNA 3.1(ϩ), previously prepared with EcoRV and NotI. Restriction analysis was performed with BstXI.
These mammalian expression plasmids were purified using the Qiagen Maxi Kit and resequenced to confirm the mutation sites determined above. The sequencing was carried out using an Applied Biosystems model 377 automatic DNA sequencer according to the manufacturer's instructions (Applied Biosystems, Foster City, CA).
Preparation of nuclear extracts from kidney cancer tissues
The buffers used for isolation were as described by Kane (33) . All buffers were supplemented with pepstatin A (final concentration 1 µg/ml), leupeptin (1 µg/ml), aprotinin (2 µg/ml) and PMSF (0.5 mM). Up to 100 mg of the tissue was manually homogenized in a glass-teflon homogenizer in 1 ml of ice-cold STM buffer (0.25 M sucrose, 20 mM Tris-HCl, pH 7.85, 1.1 mM MgCl 2 ) and centrifuged at 1000 g for 10 min at 4°C. The pellet was washed twice in 1 ml of STM buffer with 0.5% Triton X-100, followed by centrifugation under the conditions described above. The final pellet was resuspended in 0.1 ml KSTM ϩ 20% glycerol buffer (0.25 M sucrose, 20 mM Tris-HCl, 1.1 mM MgCl 2 , 0.4 M KCl, 20% glycerol, 5 mM DTT), sonicated and then incubated on ice for 30 min with vortexing every 5 min to extract the soluble nuclear proteins. After solubilization, the suspension was centrifuged at 12 000 g for 15 min at 4°C. The amount of protein in the supernatant was quantified by spectrophotometry with Bio-Rad Protein Assay buffer at 595 nm and stored in 10 µl aliquots at -75°C.
Electrophoresis mobility shift assay (EMSA)
TR proteins were synthesized by in vitro transcription/translation using the TNT coupled reticulocyte kit according to the manufacturer's instructions (Promega). 32 P-labeled TRE-Lys was prepared as previously described (30) . The in vitro translated TR proteins were quantified by measuring the intensity of the 35 S-labeled protein bands after SDS-PAGE. For EMSA, identical amounts of TRs were incubated with the 32 P-labeled TRE in the presence or absence of RXRβ. After electrophoresis, TR homodimers and heterodimers were visualized by autoradiography.
To further evaluate whether the DNA-binding activity of TRs was altered in RCCC, gel mobility shift assays were performed with 7.5-10 µg nuclear extract isolated from tumors and their respective controls. The probe was a double-stranded DNA containing TRE-DR4 (5Ј-GATCGCAGGTCATTTCA-GGACAGCGATC-3Ј). Mutated TRE served as a non-specific competitor (5Ј-GGCAAATCATTTCAAGACAG-3Ј). Nuclear extracts were incubated at room temperature for 20 min in binding buffer containing 20 mM Tris-HCl, pH 7.5, 50 mM KCl, 2 mM DTT, 0.1% Triton X-100, 6% glycerol, in the presence of 250 ng dI·dC, 1 ng probe and a 10 times excess of specific or non-specific competitor. For supershift experiments, 1 µg mouse monoclonal anti-TR (β1 and α1) antibody C4 (34) was added to the binding reaction.
The mixture was first incubated on ice for 30 min, followed by an additional incubation at room temperature for 20 min. The binding reactions were loaded onto a 4% native gel and electrophoresed at 150 V for 2 h at room temperature. The gel was dried and autoradiographed.
Binding of [3Ј-125 I]T 3 to TRs
The in vitro translated TR proteins were incubated with 0.2 nM [3Ј-125 I]T 3 in the presence of increasing concentrations of unlabeled T 3 . The TR-bound [3Ј-125 I]T 3 was separated from free [3Ј-125 I]T 3 as described by Zhu et al. (30) . The binding data were analyzed using equation 1 (below), based on direct competition between [3Ј-125 I]T 3 and unlabeled T 3 for a single site on the receptor. The concentration of radioactive complex is given by:
where 
Determination of the transactivation activity of TRs
To determine the T 3 -dependent transactivatioin activity, CV1 cells (6-well plates with 1ϫ10 5 cells/well) were transfected with mammalian expression plasmids for mutant (mutant TRβ1, 0.2-1.6 µg; mutant TRα1, 0.4-0.6 µg) and/or wild-type TR (TRβ1, 0.05-0.2 µg; TRα1, 0.125-0.5 µg) and 0.8 µg TRE-containing luciferase reporter gene (pTK-Pal-Luc or pTK-Lys-Luc) by the Lipofectamine method according to the manufacturer's instructions. After 16 h the medium was changed to a medium containing 10% thyroid hormonedepleted fetal bovine serum with or without 100 nM T 3 . After 24 h the cells were harvested and lysed and 100 µl was assayed for luciferase activity according to the manufacturer's instructions (BD PharMingen, San Diego, CA). The transfection efficiency was normalized to the protein concentration of the lysates.
Western blotting
Cell lysates (75 µg) from transient transfection experiments, as described above, were loaded onto a 10% SDS-PAGE gel. After electrophoresis, proteins were transferred to a PVDF membrane. The membrane was gently shaken in 10% non-fat milk in Tris-buffered saline (25 mM Tris, pH 7.4, 150 mM NaCl) for 1 h and subsquently washed three times with Tris-buffered saline.
The membrane was incubated with mouse monoclonal antibody J51 (2 µg/ ml) (36) or C4 (2 µg/ml) (34) overnight at 4°C. After washing with washing buffer (0.1% Tween 20, 25 mM Tris, pH 7.4, 150 mM NaCl), the membrane was incubated with rabbit anti-mouse Ig conjugated to horseradish peroxidase (1:2000 dilution). TR protein bands were visualized by chemiluminescence using the ECL kit (Amersham Pharmacia Biotech).
Results
Cloning of mutant TRs from patients with RCCC
The discovery of aberrant expression of TRs in RCCC (29) prompted us to clone the TR cDNAs from RCCC tumors. To control for possible artifacts, wild-type TRs (w-TRs) were also similarly cloned from normal kidney tissues. Sequencing of cDNAs shows that 40 .9% of all RCCCs tested had at least one TR mutated in the ligand-binding domain. Missense mutations within this domain were identified in seven of 22 TRβ1 cDNAs cloned from 22 tumors (31.8%) ( Figure 1A and Table I ). The mutations detected were not due to cloning artifacts because TRs were similarly cloned from the control healthy kidney tissues and were found to have the w-TR sequence. Analysis of the frequency of mutations indicates that one TRβ1 mutant (3TRβ1) was isolated from a grade G1 tumor (25% of all G1 tumors tested), three TRβ1 mutants (25TRβ1, 8TRβ1 and 18TRβ1) were from grade G2 tumors (33% of all G2 tumors tested) and three TRβ1 mutants (15TRβ1, 32TRβ1 and 6TRβ1) were from grade G3 tumors (42.8% of all G3 tumors tested) ( Table I) . Sequencing of TRα1 cDNAs cloned from 22 RCCCs revealed the presence of missense mutations in three TRα1 (13.6%) ( Figure 1B and Table I ). These three mutants were each cloned from a G1, G2 or G3 tumor (Table I) . 6TRα1 was isolated from the same G3 tumor from which 6TRβ1 was isolated (Table I ). Therefore patient 6 had mutations in both the TRα and TRβ genes ( Figure 1A and B) . Because only three TRα1 mutants were cloned from 22 tumors, it was unclear whether an increased frequency of mutant TRα1 was associated with differentiation status of the tumor. The three TRα1 mutants were from tumors with heterozygous mutation (Table I) .
Examination of the mutations shown in Figure 1 indicates that single (8TRβ1 and 25TRβ1) and multiple mutations (3TRβ1, 18TRβ1, 15TRβ1, 6TRβ1, 32TRβ1 and all TRα1 mutants) were detected. In addition to the S380F mutation, 32TRβ1 had a 26 amino acid deletion at the N-terminus. The majority of mutations were clustered in the hormone-binding domain (domains D ϩ E, see Figure 1 ). This mutation pattern is similar to that observed for TR mutants isolated from human hepatocellular carcinoma (HCC) in that single and multiple mutations were observed (17) . This is in contrast to that seen for mutations identified for patients with the genetic disease thyroid hormone resistance syndrome (RTH) (35) in which only a single mutation for each mutant was found in the TRβ gene. Analysis of the mutation patterns of RTH patients showed that the mutations are clustered in three regions in the T 3 -binding domain (36). It is of interest to point out that F451I in 3TRβ1, F451S in 8TRβ1, L456S in 6TRβ1 and M388I in 2TRα1 and 6TRα1 occurred in the first 'hot-spot'. The Y321H mutation identified in 25TRβ1 and K288E in 23TRα1 were in the second hot-spot and H184Q, S183N and R228H in 23TRα1 and A225T in 6TRα1 were in the third hot-spot identified in RTH patients (36). However, novel mutations were also observed in the DNA-binding domain for 3TRβ1 (S99R), 15TRβ1 (K155E), 2TRα1 (I116N) and 6TRα1 (I116N) ( Table I) .
T 3 -binding activity of TR mutants is impaired
To understand the functional consequences of mutations in the TRs isolated from RCCC, we first evaluated hormone-binding activity of TR mutants. Mutant TR proteins were prepared by in vitro transcription/translation. Except for 32TRβ1, which had an apparent molecular mass of 52 kDa due to deletion of 26 amino acids at the N-terminus (Figure 2A, lane 8) , all other TRβ1 mutants had sizes similar to w-TRβ1 (Figure 2A, lane  1 versus lanes 2-7) . The in vitro translated wild-type and mutant TRβ1 were full-length receptors with an apparent molecular mass of 55 kDa together with a smaller protein, most likely due to initiation from a downstream ATG (36,37). The full-length in vitro translated TRβ1 mutants were recognized by monoclonal antibody J51, whose epitope is located in the second half of the A/B domain of TRβ1 (36). The 52 kDa 32TRβ1 was recognized by monoclonal anti-TR antibody C4, whose epitope is the C-terminal 457 EVFED 461 of TRβ1 and TRα1 (data not shown; 34). Taken together, the identity of the cloned TRβ1 mutants was confirmed.
As shown in Figure 2B , the molecular sizes of TRα1 mutants were similar to that of w-TRα1 (lane 1 versus lanes 2-4). The in vitro translated wild-type and mutant TRα1 were full-length receptors with an apparent molecular weight of 49 kDa and a minor truncated protein, derived from initiation at a downstream ATG (38) . The in vitro translated TRα1 mutants were recognized by monoclonal anti-TR antibody C4 (data not shown; 34), further confirming the identity of the cloned TRα1 mutants.
To determine T 3 -binding activity, equal amounts of in vitro translated wild-type and mutant TRs were used for binding to [ 125 I]T 3 . Figure 3 shows the competitive binding displacement curves for wild-type and mutant TRs. Analyses of the binding data shown in Figure 3A indicate that w-TRβ1 bound to T 3 with a K d of 0.78 nM (Table II) . The mutations in 15TRβ1 (K155E and K411E) did not affect its T 3 -binding activity as 15TRβ1 retained the hormone-binding activity of w-TRβ1. The mutations in the hormone-binding domains of 25TRβ1 (Y321H), 6TRβ1 (E299K, H412R and L456S) and 32TRβ1 (S380F) reduced T 3 -binding activity by 35, 60 and 46%, respectively (Table II) . The mutations in the hormone-binding domains of 3TRβ1 (W219L and F451I), 8TRβ1 (F451S) and 18TRβ1 (Q252R, A387P and F417L) led to a Ͼ99% loss of T 3 -binding activity. A similar analysis of the data shown in Figure 3B indicates that the mutations in 23TRα1 (S183N, H184Q, R228H and K288E), 2TRα1 (M388I) and 6TRα1 (A225T and M388I) resulted in virtually complete loss of T 3 -binding activity (Table II) .
TR mutants exhibit aberrant DNA-binding activity
The in vitro DNA-binding activity of mutants was evaluated by EMSA using the TRE in the lysozyme gene, which consists of an inverted repeat of the two half-site binding motifs (TRELys). Table II) , all other mutants bound to TRE-Lys more weakly than w-TRβ1, with a 58-100% loss of binding (Table II) . Mutation of K155E in the DNA-binding domain of 15TRβ1 led to complete loss of DNA binding (lane 8). Except for 3TRβ1, weaker binding was also detected for heterodimeric binding with RXRβ as compared to w-TRβ1 (20-100% loss of binding; Figure 4A lane 3 versus lanes 7, 9, 11, 13, 15 and 17, and Table II ). These results indicate that mutations of TRβ1 led to alterations in the interaction of TR with TRE. Mutations in TRα1 led to a dramatic reduction in binding to TRE-Lys ( Figure 4B ). Figure 4B, lanes 5, 7 and 9 clearly show that binding of the 23TRα1, 2TRα1 and 6TRα1 mutants, respectively, to TRE-Lys as homodimers was hardly detectable (versus lane 3; see also Table II) . Binding of these mutants to TRE-Lys as heterodimers with RXRβ was also decreased by 60-90% ( Figure 4B , lane 4 versus lanes 6, 8 and 10, and Table II) .
To determine the DNA-binding characteristics of endogenous TRs in cancer tissues, nuclear extracts of RCCC tissues as well as extracts prepared from the healthy opposite kidney poles were evaluated by EMSA assay ( Figure 5A ). The DNAbinding patterns were analyzed in 20 cancer-control pairs. Binding of the TRE to TRs present in nuclear extracts of RCCC in which mutations were found was much weaker than that in the healthy controls. One representative example (a tumor from patient 18) in which no binding was detected is shown in lane 2 ( Figure 5A, lanes 2 versus 5) . No significant changes in DNA binding were found in the tumor nuclear extracts from patient 32 (see Figure 5A , lane 8 versus lane 11). The DNA-bound bands shown in lanes 5, 8 and 11 were specific because the intensities of the bands were competitively reduced in the presence of a 10-fold excess of unlabeled TRE (lanes 5, 8 and 11 versus 7, 10 and 13, respectively). No competition was seen in the presence of non-specific competitors (lanes 5, 8 and 11 versus 6, 9 and 12, respectively).
To confirm that the TRE-bound bands were due to interactions of TRs present in the nuclear extracts with TRE, supershift experiments were performed ( Figure 5B ). As shown [ Figure 5B , lane 4 for cancer tissue (patient 6) and lane 7 for the normal control], when mAb C4 (anti-TRβ1 antibody) (34) was present, the TRE-bound bands were shifted to a more retarded position (compared with lanes 2 and 5 for cancer and normal control, respectively). These results clearly show that the DNA-bound bands were due to interactions of the TRE with TRs in the nuclear extracts.
The T 3 -dependent transactivation activity of TR mutants is impaired
To further assess the functional consequences of mutations in TRs isolated from RCCC, we determined the transactivation activity of TR mutants by transient transfection assays. Mammalian expression plasmids for the mutants were cotransfected with TRE-containing reporter genes into CV-1 cells. Figure 6A compares the transactivation activity of TRβ1 mutants using a reporter containing TRE-Lys. In the absence of T 3 all mutants were more potent than w-TRβ1 in repression 30 of basal transactivation activity (bar 3 versus bars 5, 7, 9, 11, 13, 15 and 17). Except for 32TRβ1, the T 3 -dependent transactivation activities of all other mutants were reduced, ranging from 50% reduction as seen for 25TRβ1 (bar 12 versus bar 4) to a total loss of transactivation activity for 8TRβ1 (bar 8). A similar reduction in transactivation activity was detected using the reporter TRE-Pal (data not shown). The decrease in transactivation activity observed for TRβ1 mutants was not due to lower expression of the mutant receptor proteins. Preliminary experiments were carried out using western blot analysis to titrate the amounts of expression plasmid used in the transfections such that the levels of mutant receptor proteins expressed were comparable to that of w-TRβ1 ( Figure 6C) . Therefore, the impairment in transactivation activity was due to a loss of hormone binding and/or DNA binding.
Similar to the observations for TRβ1 mutants, all three TRα1 mutants were more potent repressors than w-TRα1 in the absence of T 3 ( Figure 6B, bar 3 versus bars 5, 7 and 9) . Furthermore, the T 3 -dependent transactivation activities of all three mutants were nearly completely lost (bars 6, 8 and 10). Figure 6D indicates that the loss of transactivation activity of TRα1 mutants was not due to lower expression of TRα1 mutant proteins because the levels of expression of the TRα1 mutant proteins were comparable to that of w-TRα1. Thus, the loss of transactivation activity was the consequence of loss of T 3 -binding and/or DNA-binding activity (Table II) .
Dominant negative action of TR mutants
We further evaluated the dominant negative action of TR mutants by examining their inhibitory effect on the transactivation activity of w-TRs. CV-1 cells were transfected with the w-TR expression plasmid together with a 5-or 10-fold excess of mutant expression plasmid. The transactivation activities of w-TR in the absence or presence of mutant TR were compared and the results are shown in Table III . 8TRβ1 was a strong dominant negative mutant in that 49 and 84% of the transactivation activity of w-TRβ1 was inhibited at mutant:w-TRβ1 plasmid ratios of 5:1 and 10:1, respectively. 3TRβ1 exhibited a dominant negative effect at a T 3 concentration of 10 nM. However, at a 10-fold higher T 3 concentration the dominant negative effect of 3TRβ1 was abrogated. This is consistent with the T 3 binding affinities of these two mutants (see Table II ). All other TRβ1 mutants lacked dominant negative activity (Table III) . The three TRα1 mutants, 23TRα1, 2TRα1 and 6TRα1, exhibited strong dominant negative activity in that they inhibited 63-79 and 81-86% of the transactivation activity of w-TRα1 at mutant:w-TRα1 plasmid ratios of 5:1 and 10:1, respectively (Table III) .
Discussion
The role of TRs in RCCC carcinogenesis is not known. We explored the possibility of involvement of TRs in RCCC carcinogenesis based on the consideration that TRα1 is a transcriptionally active cellular homolg of v-ErbA, which is a viral oncogene product functioning as a dominant negative receptor in the neogenesis of erythroleukemia and sarcomas (39, 40) . Furthermore, transgenic mice over-expressing v-ErbA developed liver cancer as well as thyroid abnormalities (41), indicating a critical role of v-ErbA (a mutated TRα1) in oncogenesis. We also considered involvement of the TRβ gene in RCCC carcinogenesis, because of its chromosomal localization on 3p21-p25. Previously, van den Berg et al.
reported that unknown genes localized in the 3p21 region could contribute to RCCC carcinogenesis (7) (8) (9) . The possibility that the TRβ and TRα genes could contribute to RCCC carcinogenesis is strengthened by the aberrant expression of TRs; TRα1 mRNA was decreased and TRβ1 mRNA was overexpressed in 30% and decreased in 70% of tumors (29) . Furthermore, abnormal expression of TR proteins was detected; TRα1 proteins were overexpressed and TRβ1 proteins were reduced in tumors (29) .
We therefore cloned TR cDNAs from RCCC and evaluated their functions. Sequence analyses of TR cDNAs isolated from RCCC show that the TRβ and TRα genes were mutated in seven of 22 and three of 22 tumors, respectively. These somatic mutations led to loss of the hormone-binding, DNA-binding and transcriptional activities. The extent of functional impairment depends on the sites and number of mutations in the TRs. The molecular basis of the functional impairment of these mutant TRs, however, is difficult to quantify. Most contain several mutated residues; the contributions of these changes may not be additive (42) . Furthermore, we have shown that T 3 -dependent transcriptional activation of TRs is modulated by interactions between all domains in the protein (30) . Consequently, it is difficult to predict the results of any of these changes. Interestingly, some of the mutations identified in RCCC occurred in the three 'hot-spots' in the hormone-binding domain of TRβ1 identified from patients with RTH (36). Thus, 8TRβ1 has a single mutation (F451S) in hot-spot 1 and has greatly reduced affinity for T 3 (Table II) . However, 25TRβ1, which has a single mutation (Y321H) in hot-spot 2, exhibits only a minor decrease in its affinity for T 3 , but had only 50% of the wildtype binding to the TRE. 15TRβ1 has two sequence changes, one in the DNA-binding domain (K155E) and the other in the putative dimerization interface (K411E) (43) . Consistent with these changes, this mutant retains affinity for T 3 but shows no binding to DNA. Two of the mutations in 6TRβ1 occur at the dimer interface (H412R) and near hot-spot 1 (L456S), respectively, resulting in a significant loss of binding to DNA and a minor reduction in T 3 binding. A significant reduction in T 3 binding is seen for 18TRβ1, which includes sequence changes in hot-spot 3 (Q252R) and the dimerization domain (F417L). Alterations in 3TRβ1 were found in hot-spot 1 (F451I), which is consistent with a large decrease in affinity for T 3 .
Genetic changes in the TRα1 mutants are equally complex. 2TRα1 and 6TRα1 show similar behaviour, presumably due to the same structural changes, a large reduction in affinity for the hormone and loss of homodimer binding to TRE-Lys (I116N is in the last helix of the DNA-binding domain). The very low affinity for hormone shown by 23TRα1 is readily explained by the four mutations found in its ligand-binding domain (three in hot-spot 3 and one in hot-spot 2). However, the origin of its reduced capacity to bind to DNA is far from clear and awaits elucidation.
TRα1 and TRβ1 with multiple mutations were also found in HCC (17) . All mutated TRα1 identified in HCC with known mutation sites (eight of 12 HCC evaluated) were found to have between two and four mutations. For TRβ1 mutants, 50% from HCC were found to have between two and four mutations. This is in contrast to RTH patients, in which no multiple mutation of the TRβ gene was found and, moreover, no mutation was detected in the TRα gene. The role of multiple mutations of TRs in carcinogenesis is yet to be elucidated.
Comparison of the mutation sites in TRα1 and TRβ1 mutants between RCCC and HCC (17) shows that there was only one common mutation site in TRα1, at A225, and no common mutation site was detected in TRβ1 mutants between these two cancers. In RCCC, A225 of TRα1 was mutated to T, whereas in HCC A225 was mutated to G. However, in spite of different mutations of TRs in these two cancers, functional impairment of mutant TRs derived from these two cancers was similar in that mutation led to loss of the hormone-binding, DNA-binding and transcriptional activity. Moreover, TR mutants frequently exhibited dominant negative activity (17, 44, 45) . These findings suggest that impairment of TR functions could play a critical role in the tumorigenesis of these two cancers.
At present, however, the precise roles of mutant TRs in carcinogenesis are not clear. Based on the functional impairment of TRβ1 and TRα1 mutants demonstrated in the present study, it is reasonable to postulate that the transcriptional regulation of TR-mediated genes involved in cell differentiation, proliferation (46) (47) (48) and apoptosis (49-51) is abnormally affected in RCCC expressing these mutants. In addition, functional impairment of TRβ1 and TRα1 mutants might also affect the protein-protein interactions in the network of cellular proto-oncogenes and tumor suppressors. TRs have recently been found to cross-talk with other signalling pathways. For example, TRβ1 was shown to physically associate with the tumor suppressor protein p53 and repress p53-mediated transcriptional activity. Conversely, p53 reduces the ability of TRβ1 to bind to DNA and to activate transcription (52, 53) . TRs also stimulate expression of the c-fos and c-jun proto-oncogenes, increase expression of the c-Fos and c-Jun proteins and activate AP1 transcriptional activity in a T 3 -independent pathway. In turn, both c-Fos and c-Jun inhibit T 3 -dependent transcription activation (54) (55) (56) . TRs have been shown to directly activate expression of the mdm2 oncogene, which subsequently induces rapid degradation of p53 (57, 58) and inhibits retinoblastoma tumor suppressor. Thus, functional impairment due to mutations and the aberrant expression of TRs in RCCC could result in the disarray of the normal regulatory control of cell proliferation, differentiation and apoptosis. Thus, dedifferentiated cells could again become sensitive to proliferation signals, while cells with damaged DNA are possibly not eliminated by means of apoptosis. The present study demonstrates that the percentage of mutated TRβ1 was lowest in well differentiated (G1) and highest in poorly differentiated and fast growing (G3) tumors (see Table I ). This finding is consistent with the notion that regulatory control of these processes is severely affected in poorly differentiated tumors. The functional consequences of mutations may be further accentuated by the dominant negative action of mutants. Indeed, our data clearly indicate that 3TRβ1, 8TRβ1, 23TRα1, 2TRα1 and 6TRα1 exhibit potent dominant negative activity. In addition to the loss of and/or interference with the normal functions of TRs, TR 32 mutants may act via a gain-of-function mechanism. This mode of action of mutant genes is not unprecedented, as it has been clearly documented in p53 mutants (59) . The gain-of-function of TR mutants may provide a growth advantage early in the progression of neoplastic cells, may affect genes which prevent differentiation and/or apoptosis of cells and may promote genomic instability. Any of these actions may contribute to the development of RCCC. These possibilities will await validation in future studies.
